Evaluating the Safety and Efficacy of Imatinib in Combination With Artemether and Lumefantrine for Treatment of Uncomplicated Malaria
This study is investigating an innovative approach to treating uncomplicated malaria by adding a drug called Imatinib to the current standard of care, Artemether + Lumefantrine (AL). The researchers hope this combination, known as ALIM, will clear infections faster and stop the spread of drug-resistant parasites that are becoming a major threat in Africa
⁃ For Part 1 and 2 of the study design, all individuals must meet all the inclusion criteria below:
• Patients diagnosed with symptomatic mild to moderate P. falciparum malaria with a parasite density of \>= 5000 parasites/μl
• Adult male, age 18-55 years old or adult female, age 18-55 years that are post-menopausal, or test negative on a pregnancy test and will be on active birth control through to the end of the follow up period.
• Provision of informed consent and agrees to hospital admission for 48-72hrs
• Good health condition other than malaria
• The patient has not taken anti-malarial drugs in the past 4 weeks
⁃ For Part 3 of the trial, all individuals must meet all the inclusion criteria below:
• Patients diagnosed with symptomatic mild to moderate P. falciparum malaria and a parasite density of \>= 5000 parasites/μl
• Age 12 months to below 18 years
• Presented by parent or legally accepted representative (LAR) who has consented to the participation of the child in the trial and agrees to hospital admission for 48-72hrs.
• Hb levels \> 5mg/dL
• Child has not taken anti-malarial drugs in the past 6 weeks.